article thumbnail

STAT+: ‘It’s like Groundhog Day’: The cancer drug shortage isn’t new — and neither are the solutions

STAT

” Methotrexate isn’t the only essential chemotherapy clinicians are having a hard time getting their hands on right now. Two other key chemotherapies, cisplatin and carboplatin, which are also generic injectable drugs, have been in shortage for the last few months. “It’s just so, so maddening.”

article thumbnail

EC approves first-line ovarian cancer treatment

European Pharmaceutical Review

The small molecule treatment is indicated as a first-line maintenance treatment for individuals with advanced ovarian cancer regardless of their BRCA mutation status, who have responded to first-line platinum-based chemotherapy. ” The EC based its approval the Phase III ATHENA-MONO study results.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Daiichi Sankyo grabs first approval for blood cancer drug Ezharmia

pharmaphorum

It is usually treated with chemotherapy, but has a high rate of relapse and a low five-year survival rate of between 12% and 14%. ATL is a rare and highly aggressive form of non-Hodgkin lymphoma (NHL), generally associated with infection by the HTLV-1 retrovirus, that can manifest as either a lymphoma or a leukaemia.

article thumbnail

J&J’s Darzalex Faspro is first US therapy for rare blood disorder

pharmaphorum

Until now people with AL amyloidosis have had to rely on chemotherapy, with its accompanying side effects, and other drugs to tackle organ failure once damage gets severe. Amyloid plaques can then form in multiple organs such as the heart, kidneys and liver, damaging them and in some cases leading to organ failure.

article thumbnail

Transforming oncology with antibody therapeutics

European Pharmaceutical Review

Amivantamab was the first bispecific monoclonal antibody (BsMAb) approved in the EU to treat advanced NSCLC with EGFR exon 20 insertion mutations post chemotherapy. 2012; 23(8): 6 – 9. These patients face a poorer prognosis and shorter survival rates compared with lung cancer driven by more common EGFR mutations. Cancer Ther.

article thumbnail

Drug Dosing

RX Note

To illustrate, in the management of nausea and vomiting induced by cytotoxic chemotherapy or radiotherapy, the dose of IV granisetron is 10 mcg/kg in Lexicomp , but 10-40 mcg/kg (max per dose 3mg) in British National Formulary.

article thumbnail

J&J decides against Erleada+Zytiga combination prostate cancer filing

pharmaphorum

Zytiga is the older of the two drugs and was used in the active control arm of the ACIS study, which tested the combination of Erleada (apalutamide) and Zytiga (abiraterone) in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).